Which syndrome is associated with the use of 5-fluorouracil (5FU) and capecitabine?

Which syndrome is associated with the use of 5-fluorouracil (5FU) and capecitabine?

• A. Chest Pain Syndrome
• B. Hand and Foot Syndrome
• C. Stevens-Johnson Syndrome
• D. Cardiotoxicity Syndrome

Answer: (B)

The correct response identifies Hand and Foot Syndrome as associated with the use of 5-fluorouracil (5FU) and capecitabine. This syndrome is characterized by a painful erythematous condition affecting the palms of the hands and the soles of the feet. It arises due to the toxicity of these chemotherapeutic agents, which can cause skin reactions in areas of increased friction or pressure. Hand and Foot Syndrome may present as redness, swelling, and, in severe cases, blistering or desquamation. The underlying mechanism involves the drug-induced damage to endothelial cells and the subsequent release of inflammatory mediators, leading to the symptoms observed. This side effect is particularly relevant to patients receiving these agents, as it can significantly impact their quality of life and adherence to the chemotherapy regimen. Understanding this association is vital for healthcare providers to anticipate, recognize, and manage these side effects promptly in patients undergoing treatment with 5FU or capecitabine.

The correct response identifies Hand and Foot Syndrome as associated with the use of 5-fluorouracil (5FU) and capecitabine. This syndrome is characterized by a painful erythematous condition affecting the palms of the hands and the soles of the feet. It arises due to the toxicity of these chemotherapeutic agents, which can cause skin reactions in areas of increased friction or pressure.

Hand and Foot Syndrome may present as redness, swelling, and, in severe cases, blistering or desquamation. The underlying mechanism involves the drug-induced damage to endothelial cells and the subsequent release of inflammatory mediators, leading to the symptoms observed.

This side effect is particularly relevant to patients receiving these agents, as it can significantly impact their quality of life and adherence to the chemotherapy regimen. Understanding this association is vital for healthcare providers to anticipate, recognize, and manage these side effects promptly in patients undergoing treatment with 5FU or capecitabine.